Complex Civil Litigation Law Firm

If you suffered significant losses in Kyndryl stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE: KD). STOCK DROP: On February 9, 2026, Kyndryl disclosed in a filing with the U.S. Securities and Exchange Commission that its Audit Committee is reviewing the Company’s cash management practices, related disclosures (including regarding the drivers of the Company’s adjusted free cash flow metric), and the efficacy of its internal control over financial reporting following the Company’s receipt of voluntary document requests from the SEC’s Division of Enforcement. Kyndryl further disclosed that it expects to report material weaknesses in internal control over financial reporting for multiple reporting periods. The Company also stated that its previously issued assessment of internal control over financial reporting and its independent auditor’s opinion included in its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 should no longer be relied upon. In addition, Kyndryl announced the immediate departures of its Chief Financial Officer and General Counsel and filed a Form NT 10-Q indicating that it would delay the filing of its Quarterly Report on Form 10-Q. Following these disclosures, Kyndryl’s stock price declined approximately 50% on February 9, 2026.

If you purchased or acquired securities in Inovio between October 10, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) and reminds investors of the April 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) manufacturing for Inovio’s CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107’s overall regulatory and commercial prospects were overstated; and (5) as a result, Defendants’ public statements were materially false and misleading at all relevant times.  

If you purchased or acquired securities in Paysafe between March 4, 2025 and November 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Paysafe Limited (“Paysafe” or the “Company”) (NYSE: PSFE) and reminds investors of the April 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Paysafe’s ecommerce business had significant exposure to a single high risk client; (2) as a result, the Company’s credit loss reserves and/or write-offs were understated; (3) Paysafe had an undisclosed issue with higher risk Merchant Category Codes, making its client services difficult to bank; (4) the foregoing issues were likely to have a material negative impact on the Company’s revenue growth and overall revenue mix; (5) as a result, Paysafe was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (6) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Lead Plaintiff Deadline: April 7, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.

If you suffered significant losses in Hub Group stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hub Group, Inc. (“Hub Group” or the “Company”) (NASDAQ: HUBG). Stock Drop: On February 6, 2026, Hub Group shares fell sharply, after the logistics company disclosed a $77 million accounting error related to purchased transportation costs and accounts payable, prompting a restatement of prior financial results. The company said the error did not impact cash flow, but investors reacted negatively to the disclosure, sending the stock down as much as roughly 25% intraday. The announcement coincided with the release of preliminary fourth-quarter and full-year 2025 results and a delay in filing updated financial statements.